COVID-19_1170x250

COVID-19 Vaccines Resources

By AHRMM

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus.

This webpage is intended to help keep the supply chain field informed of important updates related to the progress and distribution of COVID-19 vaccines. Resources and information will be added and updated often as new developments occur.

<< Return to AHRMM's COVID-19 page.

AHA COVID-19 Vaccines and Therapeutics

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus. As the virus surged in 2020, therapeutics were developed to treat those with COVID-19 in outpatient and inpatient settings. This webpage is intended to help keep the field informed of important updates related to the progress and distribution of COVID-19 vaccines, along with in-development therapeutics for patients with COVID-19.

CDC COVID-19 Vaccination Program Interim Playbook

This playbook serves as an interim playbook for state, territorial, tribal and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their jurisdictions.

AHRMM Webinar: COVID 19 Vaccine Supply, Distribution and Handling Overview: An Operation Warp Speed Panel Discussion

 

 

Webinar Recording and Handouts

Review the recording and materials that were made available at the December 16 webinar:

Access Webinar Recording

Access Presentation Handouts

Access Presentation Slides

Operation Warp Speed Videos

Review the videos provided by HHS and Operation Warp Speed:

View Five Things to Know About the COVID-19 Vaccine Timeline (Video)

Access Five Things to Know About Operation Warp Speed (Video)

Other News

Pfizer and BioNTech COVID-19 Vaccine

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Moderna COVID-19 Vaccine

Moderna COVID‑19 Vaccine is for use for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles. It is an investigational vaccine not licensed for any indication.

Related Resources

On-Demand Educational Webinars
Senior leaders within the finance/supply chain and risk management disciplines share their thoughts on the organizational and patient risks related…
On-Demand Educational Webinars
COVID-19 has forced us all to embrace and rely on virtual technology to conduct business. This sudden change has impacted supply chain operations and…
Toolkits/Methodology
If you’re just starting to discuss elective procedures, supply chain must continuously communicate and develop relationships with key players to ma
Podcasts
Matching Needed PPE with Donors and Hospitals: A Free HealthEquip Resource
Toolkits/Methodology
As providers begin to pivot from this pandemic back to a standard model of care, now is the time for product and service suppliers to begin…
Podcasts
Jeff Berman, Principal and Healthcare Supply Chain Practice Leader at Grant Thornton, discusses emerging trends in the health care supply chain due…